DODmitry V. Ognerubov

Dmitry V. Ognerubov

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Dmitry V. Ognerubov has a total of 106 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    MEDICAL AND ECONOMIC ANALYSIS OF THE EFFICIENCY OF PERCUTANEOUS CORONARY INTERVENTIONS WITH TRANSRADIAL ACCESS IN THE FEDERAL DISTRICTS OF THE RUSSIAN FEDERATION

    by D. Ognerubov, E. Berseneva, V. BABChENKO, E. Molohoev, E. Merkulov

    In the percutaneous coronary interventions various methods of treatment of the patients with coronary heart disease are used. The principal method is radial access owing to its advantage as compared with other ones in reducing complications and mortality. The article analyses economic efficiency of the radial access in the percutaneous coronary interventions in the federal districts of the Russian Federation.

  • ANALYZING THE BUDGET IMPACT OF NEW ORAL ANTICOAGULANTS AND ENDOVASCULAR LEFT ATRIAL AURICULAR CLOSURE IN PATIENTS WITH ATRIAL FIBRILLATION

    by Dmitry V. Ognerubov, Evgenia A. Berseneva, Alexey E. Cheberda, Batyr A. Zhakypov, Vladislav V. Babchenko, Irina A. Merkulova, Dmitry V. Pevzner, Nikolai A. Ognerubov, Evgeny V. Merkulov

    Highlights This study is the first in Russian Federation to evaluate the impact of left atrial appendage closure (LAAC) on the healthcare budget based on real clinical data. The work demonstrates the clinical and economic advantages of LAAC over conventional anticoagulant therapy in patients at high risk of complications.   Aim. To evaluate the clinical and cost-effectiveness of left atrial appendage closure (LAAC) compared with novel oral anticoagulants (NOAC) on the basis of real patient data, and to perform a scenario analysis of the impact of these approaches on the healthcare budget in the Russian Federation. Methods. The study included 145 patients divided into two groups: LAAC (n = 46) and NOAC (n = 99). The mean age was 65.5 ± 8.1 years in the LAA closure group and 67 ± 7.0 years in the NOAC group. Patients with LAA closure had a higher risk of thromboembolic and haemorrhagic complications. Direct medical costs were estimated based on the cost of procedures, drugs, and complications. Budget impact analyses were performed over a 5- and 10-year horizon, taking into account a 29% increase in the use of LAAC each year. Results. LAAC provides higher survival (95.7% vs. 79.8%) and complication-free survival (74.0% vs. 60.6%) compared to NOAC. Direct treatment costs are 405,754 RUB per patient for LAAC and 10,116 RUB for NOAC. Scenario analysis showed that over 10 years, if the share of LAA closure increases, costs will increase from 900.344 RUB billion to 920.516 billion RUB. The difference between the scenarios was 2.017 billion RUB, indicating an increase in the economic burden when the technology is scaled up. Conclusion. LAA closure is a clinically effective strategy with the potential for cost-effectiveness in the long term. It can be recommended for patients at high risk of stroke, in case of limited healthcare resources. However, successful implementation of the technology requires additional training of specialists and quality control of procedures.

  • Open Access

    Клиническая-экономическая эффективность эндоваскулярного закрытия ушка левого предсердия у пациентов с фибрилляцией предсердий и противопоказанием к приему антикоагулянтов

    by Викторович Огнерубов Дмитрий, Александровна Берсенева Евгения, Евгеньевич Чеберда Алексей, Valer'Evich Babchenko Vladislav, Алексеевна Меркулова Ирина, Вольфович Певзнер Дмитрий, Alekseevich Ognerubov Nikolai, Владимирович Меркулов Евгений

    Цель данного исследования — оценить экономическую эффективность чрескожной окклюзии ушка левого предсердия (УЛП) по сравнению со стандартной профилактикой инсульта у пациентов с фибрилляцией предсердий (ФП) и противопоказаниями к приему оральных антикоагулянтов (ОАК) с точки зрения российской системы здравоохранения. Материалы и методы: Проведен анализ данных 134 пациентов, поступивших в НМИЦ кардиологии с 2014 по 2022 годы, из которых 74 пациентам было выполнено закрытие УЛП, а 60 пациентов не получали профилактическое лечение. Затраты на лечение оценивались за 3 года. Использовались данные о частоте осложнений, выживаемости и выживаемости без осложнений, а также прямые затраты на лечение, включая стоимость госпитализации, терапию, вскрытие и похороны. Результаты: за 3 года выживаемость составила 86,5% при УЛП против 66,3% без профилактики; выживаемость без осложнений — 71,6% и 40,0% соответственно; частота ишемического инсульта — 4,1% и 30,0% соответственно. Средняя стоимость лечения на 1 пациента за 3 года: 461 015 руб. для УЛП и 101 365 руб. без профилактики; суммарные QALY — 2,119 и 1,665 соответственно; CER: 217 563 руб./QALY (УЛП) и 60 880 руб./QALY (без профилактики); инкрементальные показатели после исключения немедицинских расходов: ICERQALY = 826 850 руб./QALY, ICER по выжившим = 1 858 366 руб. за одного дополнительного выжившего пациента, ICER по выжившим без осложнений = 1 187 943 руб. за одного дополнительного выжившего без осложнений. Анализ чувствительности (±15% по ключевым параметрам стоимости и выживаемости) подтвердил устойчивость результатов относительно гипотетического порога готовности платить; при этом интерпретация проводится относительно субоптимального компаратора, что требует осторожности при переносе результатов на популяции, где ОАК возможна. Выводы: С позиции российского здравоохранения закрытие УЛП у пациентов с ФП и документированными абсолютными противопоказаниями к ОАК демонстрирует клиническую пользу и приемлемую инкрементальную стоимость на горизонте 3 лет; однако, учитывая, что сравнение выполнялось с субоптимальной по руководствам стратегией и ограничения ретроспективного дизайна/размера выборки, необходимы проспективные экономические оценки и рандомизированные клинические исследования в целевой популяции для окончательного подтверждения экономической обоснованности технологии. Study Objective. The aim of this study was to evaluate the cost-effectiveness of percutaneous occlusion of the left atrial appendage (LAA) compared with standard stroke prevention in patients with atrial fibrillation (AF) and contraindications to oral anticoagulants (OAC) from the point of view of the Russian healthcare system. Materials and Methods: We analyzed the data of 134 patients admitted to NMIC Cardiology from 2014 to 2022, of whom 74 patients underwent ULP closure and 60 patients did not receive prophylactic treatment. Treatment costs and quality of life (QALY) scores were evaluated over 3 years. Data on complication rates, survival and complication-free survival, and direct treatment costs including hospitalisation, therapy, autopsy and funeral costs were used. Results: Over 3 years, survival was 86.5% with LAAO versus 66.3% without prophylaxis; complication-free survival was 71.6% versus 40.0%, respectively; and the incidence of ischaemic stroke was 4.1% versus 30.0%, respectively. The mean 3-year cost per patient was 461,015 RUB for LAAO and 101,365 RUB without prophylaxis; total QALYs were 2.119 and 1.665, respectively; CER was 217,563 RUB/QALY (LAAO) and 60,880 RUB/QALY (no prophylaxis). Incremental estimates after excluding non-medical costs were: ICERQALY = 826,850 RUB per QALY gained, ICER per additional survivor = 1,858,366 RUB, and ICER per additional complication-free survivor = 1,187,943 RUB. One-way sensitivity analysis (±15% on key cost and survival parameters) confirmed robustness relative to a hypothetical willingness-to-pay threshold; nevertheless, interpretation is made against a suboptimal comparator, warranting caution when extrapolating to populations in whom OAC remains feasible. Conclusions: From the perspective of...

  • Open Access

    Cost-effectiveness analysis of transradial percutaneous coronary interventions

    by Moscow Russian Presidential Academy Of National Economy And Public Administration, D.V. Ognerubov, E.A. Berseneva, G.V. Bekh, V.V. Babchenko, E.V. Merkulov

    Медико-экономический анализ чрескожных коронарных вмешательств лучевым доступом

  • Open Access

    Analysis of the impact on health care system costs of endovascular left atrial appendage closure technology in patients with atrial fibrillation

    by Moscow Russian Academy Of National Economy And Public Administration Under The President Of The Russian Federation, D.V. Ognerubov, E.A. Berseneva, A.е. Cheberdа, B.A. Zhakypov, V.V. Babchenko, I.A. Merkulova, D.V. Pevzner, N.A. Ognerubov, Tambov State University named after G.R. Derzhavin, et al.

    Анализ влияния на расходы системы здравоохранения технологии эндоваскулярного закрытия ушка левого предсердия у пациентов с фибрилляцией предсердий

  • Methods of cost-effectiveness evaluation of endovascular patent foramen ovale closure for secondary prevention of cryptogenic stroke

    by D.V. Ognerubov, E.A. Berseneva, A.S. Tereshchenko, D.A. Kalin, E.V. Merkulov

    The review of articles devoted to the cost-effectiveness of percutaneous closure of the patent foramen ovale (PFO) from a taxpayer’s point of view has been conducted. A decrease in the incidence of recurrent ischaemic stroke is recorded in the correctly chosen patients after the percutaneous closure of the PFO. Patients with cryptogenic stroke associated with FPO are predominantly under the age of 60, that is, at the peak of economic performance and are vulnerable to long-term disability. To assess the cost-effectiveness of FPO closure in combination with different types of treatment, Markov’s models of patients with stroke in different studies, including six health conditions (stable post-stroke, transient ischaemic attack, post-transient ischaemic attack, clinical ischaemic stroke, post-clinical ischaemic stroke and death) were considered. Assessment of 5-year time horizon, costs and utility of FPO endovascular closure technology, incremental «cost-effectiveness» ratio (ICER) and total costs for quality-adjusted life year (QALY) has been conducted in comparison with medical treatment. Mechanisms and proposals for the use of appropriate models in the Russian patients’ population are outlined.

  • Open Access

    Embolic myocardial infarction associated with patent foramen ovale: a case series

    by A. M. Pivtsova, D. Yu. Shchekochikhin, D. V. Ognerubov, A. A. Agadzhanyan, A. A. Bogdanova, M. I. Makeev, D. V. Pevzner, Е. V. Merkulov, D. A. Andreev, M. Yu. Gilyarov

    A patent foramen ovale (PFO) is a fairly common mild cardiac defect that causes a shunting across the atrial septum. PFO is also a known risk factor for cryptogenic stroke. Much less frequently, PFO is associated with non-cerebral systemic embolic events. The article describes a case series of paradoxical embolism of the coronary arteries (CA), which caused myocardial infarction (MI). The presence of PFO was confirmed by imaging techniques. Subsequently, the patients underwent successful endovascular closure of the PFO. Thus, paradoxical CA embolism is a rare and underdiagnosed cause of acute MI. It should be considered in patients with MI and a low risk of atherosclerotic coronary artery disease. However, in most cases, it is not possible to verify the source of the embolism. The significance of occluder implantation as one of the treatment tactics requires further clarification.


  • Open Access

    Analysis of radial artery occlusion causes and methods of its prevention after interventions using radial access. Results of the APRIORI study

    by D. V. Ognerubov, S. I. Provatorov, E. V. Merkulov, A. S. Merkulov, K. I. Kupina, O. A. Pogorelova, М. И. Трипотень, T. V. Balakhonova, D. M. Kairaliev, A. E. Grossman, et al.

    Aim. To study predictors of radial artery occlusion (RAO) and ways to prevent it after interventions using radial access.Material and methods. The study consisted of prospective and retrospective parts. The total number of included patients was 2284. Patients undergoing interventions by radial access in various medical organizations were retrospectively considered. The prospective study included 1284 patients who were subject to interventional treatment. Patients were randomized into two groups as follows: in group 1, hemostasis was performed within 4 hours, in group 2 — >6 hours. All patients underwent a bedside Barbeau test with a pulse oximeter and an ultrasound of access arteries to determine the radial artery patency/occlusion.Results. The RAO rate in the retrospective part was 21,8%, while in the prospective one — 10,1% with long-term hemostasis and 1,4% with short-term hemostasis (pConclusion. The main predictors of RAO were type 2 diabetes, an increase in hemostasis duration, female sex, smoking, and the artery-to-introducer diameter ratio. Taking statins, anti-ischemic and antihypertensive agents does not have a protective effect on RAO rate.

  • Device-Related Thrombus After Left Atrial Appendage Closure: Data on Thrombus Characteristics, Treatment Strategies, and Clinical Outcomes From the EUROC-DRT-Registry

    by Alexander Sedaghat, Vivian Vij, Baravan Al-Kassou, Steffen Gloekler, Roberto Galea, Monika Fürholz, Bernhard Meier, Marco Valgimigli, Gilles O’hara, Dabit Arzamendi, et al.

    Background: Left atrial appendage closure is an established therapy in patients with atrial fibrillation. Although device-related thrombosis (DRT) is relatively rare, it is potentially linked to adverse events. As data on DRT characteristics, outcome, and treatment regimen are scarce, we aimed to assess these questions in a multicenter approach. Methods: One hundred fifty-six patients with the diagnosis of DRT after left atrial appendage closure were included in the multinational EUROC-DRT registry. Baseline characteristics included clinical and echocardiographic data. After inclusion, all patients underwent further clinical and echocardiographic follow-up to assess DRT dynamics, treatment success, and outcome. Results: DRT was detected after a median of 93 days (interquartile range, 54–161 days) with 17.9% being detected >6 months after left atrial appendage closure. Patients with DRT were at high ischemic and bleeding risk (CHA 2 DS 2 -VASc 4.5±1.7, HAS-BLED 3.3±1.2) and had nonparoxysmal atrial fibrillation (67.3%), previous stroke (53.8%), and spontaneous echo contrast (50.6%). The initial treatment regimens showed comparable resolution rates (antiplatelet monotherapy: 57.1%, dual antiplatelet therapy: 85.7%, vitamin K antagonists: 80.0%, novel oral anticoagulants: 75.0%, and heparin: 68.6%). After intensification or switch of treatment, complete DRT resolution was achieved in 79.5% of patients. Two-year follow-up revealed a high risk of mortality (20.0%) and ischemic stroke (13.8%) in patients with DRT. Patients with incomplete DRT resolution showed numerically higher stroke rates and increased mortality rates (stroke: 17.6% versus 12.3%, P =0.29; mortality: 31.3% versus 13.1%, P =0.05). Conclusions: A substantial proportion of DRT is detected >6 months after left atrial appendage closure, highlighting the need for imaging follow-up. Patients with DRT appear to be at a high risk for stroke and mortality. While DRT resolution was achieved in most patients, incomplete DRT resolution appeared to identify patients at even higher risk. Optimal DRT diagnostic criteria and treatment regimens are warranted.


  • Open Access

    A Randomized Trial Comparing Short versus Prolonged Hemostasis with Rescue Recanalization by Ipsilateral Ulnar Artery Compression: Impact on Radial Artery Occlusion—The RESCUE-RAO Trial

    by Dmitrii Ognerubov, Alexander Sedaghat, Sergey Provatorov, Andrey Tereshchenko, Olivier Bertrand, Ivo Bernat, Goar Arutyunyan, Olga Pogorelova, Maria Tripoten, Tatyana Balakhonova., et al.

    Background. Despite the enormous benefits of radial access, this route is associated with a risk of radial artery occlusion (RAO). Objective. We compared the incidence of RAO in patients undergoing transradial coronary angiography and intervention after short versus prolonged hemostasis protocol. Also we assessed the efficacy of rescue 1-hour ipsilateral ulnar artery compression if RAO was observed after hemostasis. Material and Methods. Patients referred for elective transradial coronary procedures were eligible. After 6 F radial sheath removal, patients were randomized to short (3 hours) (n = 495) or prolonged (8 hours) (n = 503) hemostasis and a simple bandage was placed over the puncture site. After hemostasis was completed, oximetry plethysmography was used to assess the patency of the radial artery. Results. One thousand patients were randomized. Baseline characteristics were similar between both groups with average age 61.4 ± 9.4 years (71% male) and PCI performed on half of the patients. The RAO rate immediately after hemostasis was 3.2% in the short hemostasis group and 10.1% in the prolonged group ( ). Rescue recanalization was successful only in the short group in 56.2% (11/19); at hospital discharge, RAO rates were 1.4% in the short group and 10.1% in the prolonged group ( ). Conclusion. Shorter hemostasis was associated with significantly less RAO compared to prolonged hemostasis. Rescue radial artery recanalization was effective in > 50%, but only in the short hemostasis group.